Pandemic Perspectives: NCATS Director Urges Rare Disease Community To Push Against Return To Clinical Trial Status Quo
Chris Austin argued the rare disease community deserves the same “movement of heaven and earth” mentality as was employed for COVID-19.
You may also be interested in...
One such trial is being developed, but was needed early in the pandemic to answer many lingering questions about potential COVID-19 treatments.
Stephen Hahn also said the expedited approval process could be even more efficient.
Both sides want enhancements to deal with growth in cell and gene therapy, as well as work on regulatory decision tools and finance issues.